OpenEvidence's Approach to Hospitals: A New Era in Pharma

OpenEvidence's Approach to Hospitals: A New Era in Pharma

OpenEvidence is pitching hospitals with a message that cuts against decades of pharma distrust: "We're not crazy monsters." At the STAT Breakthrough Summit West on May 19, 2026, co-founder and CTO Zachary Ziegler outlined a structured plan for OpenEvidence's approach to hospitals that could reshape how pharmaceutical companies think about institutional partnerships, point-of-care AI, and competitive positioning against entrenched clinical decision-support incumbents like UpToDate. For BD and strategy teams, the signal is worth parsing in detail.

Key Takeaways

• OpenEvidence is pivoting from physician-facing growth to institutional hospital partnerships — a move that could open new pharma commercial channels but also raises questions about data governance and regulatory compliance under frameworks like the FDA's AI/ML Software as a Medical Device guidance.
• The company is positioning itself as a transparency-first alternative to legacy clinical decision-support tools, directly addressing hospital administrators' skepticism toward AI vendors with opaque data practices — a stance that mirrors growing EMA expectations around algorithmic transparency in clinical evidence.
• OpenEvidence's rapid physician adoption signals serious institutional momentum, but its withdrawal from the EU and UK over regulatory uncertainty underscores the fragility of cross-border AI health-tech expansion — a cautionary data point for pharma teams evaluating similar partnerships.
• Clinical validation exists but remains limited. A peer-reviewed study rated the platform high in clarity, relevance, and evidence-based support, though its retrospective design constrained conclusions about real-world clinical impact.

What happened?

On May 19, 2026, at the STAT Breakthrough Summit West in San Francisco, OpenEvidence co-founder and CTO Zachary Ziegler took the stage with a pitch that was as much about reputation management as it was about product. Speaking to an audience of hospital administrators and health-system executives, Ziegler acknowledged the elephant in the room: the pharmaceutical industry's credibility problem. His message, as reported by STAT, was blunt — "We're not crazy monsters" — a line designed to draw a sharp line between OpenEvidence's AI-driven clinical evidence platform and the broader pharma ecosystem that hospitals have long viewed with suspicion.

The pitch centered on OpenEvidence's ambition to move beyond its existing base of individual physician users and forge direct institutional partnerships with hospitals. Ziegler emphasized data transparency, ethical AI deployment, and a commitment to evidence-based outputs drawn from trusted sources including JAMA and the JAMA Network specialty journals, as well as an official AI collaboration with the National Comprehensive Cancer Network (NCCN) that incorporates NCCN Guidelines® Treatment Algorithms into the platform's content.

This wasn't a product demo. It was a trust-building exercise — one that implicitly acknowledged that no AI health-tech company can scale into hospital systems without first overcoming institutional resistance rooted in years of problematic vendor relationships.

What does it mean for pharma BD and regulatory teams?

OpenEvidence's hospital pitch carries several layers of strategic relevance for pharmaceutical companies. First, consider the competitive benchmarking angle. OpenEvidence has been called the fastest-growing application for physicians in history, a claim backed by significant venture funding. That growth trajectory puts it in direct competitive territory with UpToDate, the Wolters Kluwer-owned clinical decision-support tool that has long been the default in hospital settings. For pharma companies that rely on UpToDate as a channel for clinical evidence dissemination, OpenEvidence's institutional ambitions represent both a potential new partner and a potential disruptor.

Second, the transparency pitch matters for regulatory strategy. As the FDA continues to refine its framework for AI/ML-enabled medical devices, hospital systems are under increasing pressure to vet the algorithmic tools they adopt. OpenEvidence's emphasis on sourcing from peer-reviewed journals and established clinical guidelines — rather than proprietary or opaque datasets — is a direct response to this pressure. Pharma teams evaluating AI partnerships should note that regulatory-compliant evidence chains are becoming a procurement prerequisite, not a nice-to-have.

Third, OpenEvidence's retreat from the EU and UK markets over "mounting regulatory uncertainty" is a signal that cannot be ignored. The company's decision to withdraw rather than navigate fragmented AI governance frameworks suggests that cross-border health-tech scaling remains fraught. For pharma BD teams structuring international digital health partnerships, this is a concrete data point: regulatory divergence between the US, EU, and UK is now a material business risk for AI vendors, and by extension, for the pharma companies that integrate their tools. The SEC filings from public health-tech companies increasingly flag regulatory fragmentation as a risk factor in annual reports, reinforcing the point.

Finally, there's the question of clinical legitimacy. A study published in PMC found that OpenEvidence was rated high in clarity, relevance, and evidence-based support, reinforcing physician decisions in common chronic conditions. While the study's retrospective design limited its ability to measure impact on clinical decision-making, the conclusion that OE "shows promise in augmenting the primary care physician" provides a baseline of academic validation that pharma medical affairs teams can reference when assessing the platform's credibility.

Why is OpenEvidence withdrawing from the EU and UK?

OpenEvidence exited the European Union and UK markets citing mounting regulatory uncertainty regarding the treatment of AI in healthcare. The decision highlights the growing fragmentation in global AI governance and serves as a cautionary signal for pharma companies structuring cross-border digital health partnerships. Unlike the FDA's relatively centralized approach to AI/ML-enabled medical devices, the EU's regulatory environment — shaped by the AI Act, the Medical Device Regulation, and country-level implementation variances — presents a patchwork of compliance obligations. For OpenEvidence, the cost-benefit calculation favored retreat over adaptation. For pharma BD teams, the lesson is concrete: vendor regulatory risk profiles must now be assessed on a jurisdiction-by-jurisdiction basis, not assumed to scale globally from a US launch.

How does OpenEvidence compare to UpToDate?

OpenEvidence positions itself as a next-generation alternative to UpToDate, emphasizing AI-driven synthesis of peer-reviewed evidence and algorithmic transparency. While UpToDate remains the entrenched incumbent in hospital systems, OpenEvidence's rapid physician adoption — described as the fastest-growing physician application in history — suggests it is gaining meaningful ground. The key differentiator in OpenEvidence's pitch is its explicit commitment to data sourcing transparency, a direct response to hospital administrators' skepticism toward opaque AI tools. For pharma commercial teams, the competitive question is whether OpenEvidence's institutional push will erode UpToDate's dominance as the primary channel for point-of-care clinical evidence — and whether that shift creates new opportunities for pharma companies to influence prescribing behavior through a different digital conduit.

What should pharma teams watch next?

Three things. First, whether OpenEvidence can convert its physician-level adoption into signed hospital system contracts — institutional procurement cycles are long, and pitch-stage enthusiasm doesn't always translate to deployment. Second, how the company navigates the FDA's evolving AI/ML regulatory framework, particularly if its hospital-facing product triggers Software as a Medical Device classification. Third, whether UpToDate or other incumbents respond with their own transparency-focused counter-pitches, which could trigger a broader competitive repositioning across the clinical decision-support market — and reshape the channels through which pharma companies reach clinicians at the point of care. The annual reports of publicly traded health-tech peers suggest that institutional sales cycles in this space typically span 12 to 24 months, so near-term contract announcements would be a strong leading indicator.

Frequently Asked Questions

Related coverage

• FDA Flavored Vape Ban: Youth Risk and Pharma Implications